Results 1 to 10 of about 67,152 (253)
Акушерство, гинекология и репродукция, 2016 Several direct oral anticoagulants (DOACs), namely, apixaban, rivaroxaban, and dabigatran etexilate, are currently licensed in Europe and the United States for various thromboembolic indications.
I. Tzoran, B. Brenner
doaj +7 more sources
Reversal of direct oral anticoagulants [PDF]
Vascular Health and Risk Management, 2017 Mosaad Almegren Department of Medicine, Al Imam Mohammad Ibn Saud Islamic University, Riyadh, Kingdom of Saudi Arabia Abstract: Reversal agents for direct oral anticoagulants (DOACs), including factor X inhibitors and direct thrombin inhibitors, are a ...
Almegren M
doaj +7 more sources
A three-year prospective study of the presentation and clinical outcomes of major bleeding episodes associated with oral anticoagulant use in the UK (ORANGE study) [PDF]
Haematologica, 2018 The outcomes of patients developing major bleeding while on oral anticoagulants remain largely unquantified. The objectives of this study were to: (i) describe the burden of major hemorrhage associated with all available oral anticoagulants in terms of ...
Laura Green +10 more
doaj +5 more sources
Direct oral anticoagulants and venous thromboembolism [PDF]
European Respiratory Review, 2016 Venous thromboembolism (VTE), consisting of deep vein thrombosis and pulmonary embolism, is a major clinical concern associated with significant morbidity and mortality.
Massimo Franchini +1 more
doaj +5 more sources
Direct-acting oral anticoagulants: An overview
Saudi Journal of Medicine and Medical Sciences, 2017 In today's practice, an increasing number of patients are prescribed anticoagulant therapy. Short-term anticoagulation as a primary or secondary prophylaxis of thrombosis is standard of care in many clinical indications.
Hatem H Salem
doaj +4 more sources
Overview of the Direct Oral Anticoagulants [PDF]
Journal of the Minneapolis Heart Institute Foundation, 2017 ABSTRACT Over the past 6 decades, warfarin has proven efficacious in reducing stroke risk in patients with atrial fibrillation and reducing the risk of recurrent venous thromboembolism in patients with acute deep vein thrombosis or pulmonary embolism.
Nedaa Skeik +2 more
openalex +3 more sources
Safety and interaction of direct oral anticoagulants with antiarrhythmic drugs
Российский кардиологический журнал, 2021 The use of direct oral anticoagulants minimized the risks associated with vitamin K antagonist (warfarin) therapy. Currently, direct oral anticoagulants have priority over warfarin for the prevention of thromboembolic events in patients with atrial ...
B. A. Tatarsky, N. V. Kazyonnova
doaj +1 more source
Direct oral anticoagulants in antiphospholipid syndrome
Revista Brasileira de Reumatologia, 2016 Jozélio Freire de Carvalho +2 more
doaj +4 more sources
Direct oral anticoagulants uptake and an oral anticoagulation paradox [PDF]
British Journal of Clinical Pharmacology, 2020 Oral anticoagulation (OAC) for stroke prevention in patients with atrial fibrillation is underutilised. One of the impediments to warfarin therapy is the frequent monitoring required, usually at a specialised warfarin clinic. The advent of direct oral anticoagulants (DOACs) facilitates OAC therapy without an onerous monitoring regimen. This benefit may
Cormac Kennedy +4 more
openaire +3 more sources
Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review
Рациональная фармакотерапия в кардиологии, 2022 The last decade has dramatically changed the strategy of anticoagulant therapy in patients with atrial fibrillation. Direct oral anticoagulants have replaced vitamin K antagonists: either direct thrombin blockers (dabigatran) or factor IIa blockers ...
B. A. Tatarsky, N. V. Kazennova
doaj +1 more source